Auf dieser Website kommen Cookies zum Einsatz. Für weitere Informationen über Cookies, klicken Sie bitte auf den Link Datenschutz. Wenn Sie „Ok“ klicken und die Website weiter nutzen, gehen wir von Ihrem Einverständnis aus.

Cookies are used on this website. For more information about cookies, please click on the Privacy Policy link. If you click on "Ok" and continue to use the website, we assume your agreement.

Origenis beruft Dr. Peter Seufer-Wasserthal zum Chief Business Officer

Martinsried, Germany, March 22, 2018 - Origenis GmbH, a German biotech company
specializing in the discovery and development of highly selective small molecule kinase
inhibitors for CNS disorders, today announced the appointment of Dr. Peter Seufer-
Wasserthal as Chief Business Officer.

Dr. Seufer-Wasserthal brings 25 years experience in technology oriented business
development to the company. Prior to joining Origenis, he served as Vice President Business
Development at Intrexon Corporation (NYSE: XON) and before that held several senior
executive and business development positions at Codexis, Inc., (NASDAQ: CDXS), where
he closed numerous licensing, research and supply agreements. Before Codexis, Dr. Seufer-
Wasserthal managed a broad range of drug discovery collaborations, licensed pre-clinical
candidates to Pharma partners and directed several drug development projects in the
position of Senior Vice President of Business Development at Morphochem and Evotec. He
holds a Ph.D. in organic chemistry from the Technical University of Graz.

Origenis´CEO Michael Almstetter welcomed Dr. Seufer-Wasserthal: “We are excited to have
Peter join at this stage of our growth. Beyond our focus on highly selective small molecule
kinase inhibitors for CNS disorders, Origenis has developed a comprehensive set of non-
CNS and ophthalmological assets that are validated by several Pharma partnerships and
have the potential to significantly contribute to the company's top line. Peter will lead Origenis´
business activities and grow our relationships in the pharmaceutical market to establish
additional collaborations with leading companies in the field. I am confident that his deep
industry insight and proven closing capabilities will be a tremendous asset to Origenis.”-ends-

Download press release